Europäische Union - Kroatisch - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (kao fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastična sredstva - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Полицитемия vjera (mf)jakavi indiciran za liječenje odraslih bolesnika s полицитемия vjera, koje su otporne na ili netoleranciju hidroksiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostali dermatološki pripravci - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Kroatien - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - sunitinibmalat - kapsula, tvrda - urbroj: jedna kapsula sadrži 12,5 mg sunitiniba u obliku sunitinibmalata

Kroatien - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - sunitinibmalat - kapsula, tvrda - urbroj: jedna kapsula sadrži 25 mg sunitiniba u obliku sunitinibmalata

Kroatien - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - sunitinibmalat - kapsula, tvrda - urbroj: jedna kapsula sadrži 50 mg sunitiniba u obliku sunitinibmalata

Kroatien - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - sunitinibmalat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži sunitinibmalat, što odgovara 12,5 mg sunitiniba

Kroatien - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - sunitinibmalat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži sunitinibmalat, što odgovara 25 mg sunitiniba

Kroatien - Kroatisch - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - sunitinibmalat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži sunitinibmalat, što odgovara 50 mg sunitiniba